|  |  | 

India Top Headlines

Virafin: Zydus Cadila Receives DCGI Approval for Hepatitis Drug to Treat Covid-19 | India News


NEW DELHI: Pharmaceutical firm Zydus Cadila said on Friday that it received emergency restricted-use approval from India’s drug regulator for the use of pegylated interferon alfa-2b (PegIFN) in the treatment of moderate Covid-19 infection. in adults.
Earlier in the month, the company had applied for DCGI approval for the additional indication of the Pegylated hepatitis drug Interferon Alpha-2b for the treatment of Covid-19.
The company received emergency restricted use approval from the Controller General of Medicines of India (DCGI) for the use of ‘Virafin’, PegIFN in the treatment of moderate Covid-19 infection in adults, Zydus Cadila said in a presentation. regulatory.
PegIFN has a very well established safety with multiple doses in patients with chronic hepatitis B and C for many years.
A single-dose subcutaneous regimen of the antiviral Virafin will make treatment more convenient for patients, according to the document.
When administered early during Covid, Virafin will help patients recover faster and avoid many of the complications. It will be available with a prescription from a medical specialist for use in a hospital / institutional setting, said Zydus Cadila.
“The fact that we can offer therapy that significantly lowers viral load when delivered early can help improve disease management. It comes at a much-needed time for patients and we will continue to provide them with access to critical therapies in this battle. against Covid-19, “said Cadila Healthcare physician Sharvil Patel.
Shares of Cadila Healthcare, the Zydus Group’s publicly traded entity, closed at Rs 571.20 per script on BSE, up 3.43 percent from their previous close.

Original source